Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-Li  Lim; John Reynolds; Hang Quach; Anna  Hutchinson; Ian H. Kerridge; Jane  Estell; Wojt Janowski; Craig Thoams Wallington-Beddoe; Anna Kalff; Flora Yuen; Andrew Spencer

doi:10.1182/blood-2021-152102

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-Li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H. Kerridge, Jane Estell, Wojt Janowski, Craig Thoams Wallington-Beddoe, Anna Kalff, Flora Yuen, Andrew Spencer

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

BACKGROUND

Bortezomib-based induction (V-IND) approaches are used in >90% of Australian newly diagnosed transplant eligible multiple myeloma (NDTE MM) patients (pts) with a maximum of 4 cycles of V-IND therapy available via the pharmaceutical benefits scheme (PBS) prior to a planned autologous stem cell transplantation (ASCT). However, NDTE MM patients failing V-IND (defined as best response < partial response [PR]) demonstrate shortened survival and continue to represent a sub-group of MM where a clear unmet medical need persists. The ALLG MM21 was designed to evaluate the efficacy of an early response adapted approach with a switch to an intensive Daratumumab-lenalidomide-dexamethasone (DRd)-based salvage-ASCT- consolidation strategy in patients failing V-IND.

Original language	English
Article number	1665
Number of pages	3
Journal	Blood
Volume	138
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2021-152102
Publication status	Published - Nov 2021

Keywords

Daratumumab
Lenalidomide
Dexamethasone
Myeloma
Bortezomib
Therapy
DRd

Access to Document

10.1182/blood-2021-152102Licence: In Copyright

Fingerprint

Dive into the research topics of 'Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy'. Together they form a unique fingerprint.

Cite this

Lim, S-L., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I. H., Estell, J., Janowski, W., Wallington-Beddoe, C. T., Kalff, A., Yuen, F., & Spencer, A. (2021). Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood, 138(Supplement 1), Article 1665. https://doi.org/10.1182/blood-2021-152102

@article{5d21a87e19b94f0abaa7916076c5c70d,

title = "Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy",

abstract = "BACKGROUNDBortezomib-based induction (V-IND) approaches are used in >90% of Australian newly diagnosed transplant eligible multiple myeloma (NDTE MM) patients (pts) with a maximum of 4 cycles of V-IND therapy available via the pharmaceutical benefits scheme (PBS) prior to a planned autologous stem cell transplantation (ASCT). However, NDTE MM patients failing V-IND (defined as best response < partial response [PR]) demonstrate shortened survival and continue to represent a sub-group of MM where a clear unmet medical need persists. The ALLG MM21 was designed to evaluate the efficacy of an early response adapted approach with a switch to an intensive Daratumumab-lenalidomide-dexamethasone (DRd)-based salvage-ASCT- consolidation strategy in patients failing V-IND.",

keywords = "Daratumumab, Lenalidomide, Dexamethasone, Myeloma, Bortezomib, Therapy, DRd",

author = "Sueh-Li Lim and John Reynolds and Hang Quach and Anna Hutchinson and Kerridge, {Ian H.} and Jane Estell and Wojt Janowski and Wallington-Beddoe, {Craig Thoams} and Anna Kalff and Flora Yuen and Andrew Spencer",

year = "2021",

month = nov,

doi = "10.1182/blood-2021-152102",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

number = "Supplement 1",

}

Lim, S-L, Reynolds, J, Quach, H, Hutchinson, A, Kerridge, IH, Estell, J, Janowski, W, Wallington-Beddoe, CT, Kalff, A, Yuen, F & Spencer, A 2021, 'Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy', Blood, vol. 138, no. Supplement 1, 1665. https://doi.org/10.1182/blood-2021-152102

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. / Lim, Sueh-Li ; Reynolds, John; Quach, Hang et al.
In: Blood, Vol. 138, No. Supplement 1, 1665, 11.2021.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Preliminary Analysis of the MM21 Trial

T2 - Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

AU - Lim, Sueh-Li

AU - Reynolds, John

AU - Quach, Hang

AU - Hutchinson, Anna

AU - Kerridge, Ian H.

AU - Estell, Jane

AU - Janowski, Wojt

AU - Wallington-Beddoe, Craig Thoams

AU - Kalff, Anna

AU - Yuen, Flora

AU - Spencer, Andrew

PY - 2021/11

Y1 - 2021/11

N2 - BACKGROUNDBortezomib-based induction (V-IND) approaches are used in >90% of Australian newly diagnosed transplant eligible multiple myeloma (NDTE MM) patients (pts) with a maximum of 4 cycles of V-IND therapy available via the pharmaceutical benefits scheme (PBS) prior to a planned autologous stem cell transplantation (ASCT). However, NDTE MM patients failing V-IND (defined as best response < partial response [PR]) demonstrate shortened survival and continue to represent a sub-group of MM where a clear unmet medical need persists. The ALLG MM21 was designed to evaluate the efficacy of an early response adapted approach with a switch to an intensive Daratumumab-lenalidomide-dexamethasone (DRd)-based salvage-ASCT- consolidation strategy in patients failing V-IND.

AB - BACKGROUNDBortezomib-based induction (V-IND) approaches are used in >90% of Australian newly diagnosed transplant eligible multiple myeloma (NDTE MM) patients (pts) with a maximum of 4 cycles of V-IND therapy available via the pharmaceutical benefits scheme (PBS) prior to a planned autologous stem cell transplantation (ASCT). However, NDTE MM patients failing V-IND (defined as best response < partial response [PR]) demonstrate shortened survival and continue to represent a sub-group of MM where a clear unmet medical need persists. The ALLG MM21 was designed to evaluate the efficacy of an early response adapted approach with a switch to an intensive Daratumumab-lenalidomide-dexamethasone (DRd)-based salvage-ASCT- consolidation strategy in patients failing V-IND.

KW - Daratumumab

KW - Lenalidomide

KW - Dexamethasone

KW - Myeloma

KW - Bortezomib

KW - Therapy

KW - DRd

U2 - 10.1182/blood-2021-152102

DO - 10.1182/blood-2021-152102

M3 - Meeting Abstract

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

IS - Supplement 1

M1 - 1665

ER -

Lim S-L, Reynolds J, Quach H, Hutchinson A, Kerridge IH, Estell J et al. Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood. 2021 Nov;138(Supplement 1):1665. doi: 10.1182/blood-2021-152102